Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study.

Signal transduction and targeted therapy - 28 Aug 2025

Li Ning, Ou Wei, Cheng Chao, You Jian, Yang Lin, Chen Feng-Xia, Liang Yi, Yang Zhixiong, Wang Bao-Xiao, Chang Zeng-Hao, Lin Yao-Bin, Yang Weixiong, Xu Feng, Ding Guanggui, Chen Xian-Shan, Hu Ronggui, Li Shujun, Jiang Hao, Hu Xin-Xin, Long Hao, Wang Si-Yu

Abstract excerpt

The efficacy, safety and ideal treatment duration of an adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for patients with resected EGFR-mutated non-small-cell lung cancer (NSCLC) were not known until 2014, when this study was initiated. In this phase 3 ICTAN trial (GASTO1002, NCT01996098), patients with completely resected, EGFR-mutated, stage II-IIIA NSCLC after adjuvant...

Topics

Join the communities discussing this publication.

Carcinoma, Non-Small-Cell Lung
Chemotherapy, Adjuvant
Crown Ethers
Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Staging

Source

Open in PubMed Open full text

Identifiers

PMID: 40866342
DOI: 10.1038/s41392-025-02358-w
PMCID: PMC12391381

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study.PMID 40866342Read ↗

Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.Semantic proximity Read ↗

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.Semantic proximity Read ↗

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.Semantic proximity Read ↗

Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis.Semantic proximity Read ↗

[Expert consensus on icotinib as adjuvant therapy for non-small cell lung cancer].Semantic proximity Read ↗

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.Semantic proximity Read ↗

Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.Semantic proximity Read ↗

Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.Semantic proximity Read ↗

The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer.Semantic proximity Read ↗

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.Semantic proximity Read ↗

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.Semantic proximity Read ↗

Efficacy and safety of adjuvant EGFR-TKIs for non-small cell lung cancer with EGFR mutations after surgery: an updated meta-analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.